Enterprise Value

191.4M

Cash

71.22M

Avg Qtr Burn

N/A

Short % of Float

3.43%

Insider Ownership

17.39%

Institutional Own.

59.28%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NERLYNX Details
Metastatic HER2-positive breast cancer

Approved

Quarterly sales

NERLYNX Details
HER2-positive breast cancer

Approved

Quarterly sales

Alisertib Details
Cancer, Small cell lung cancer

Phase 3

Update

Neratinib Details
Metastatic Cervical Cancers

Phase 2

Data readout

Alisertib (2 combo trials) Details
Breast cancer, ER+/HER2- breast cancer

Phase 2

Data readout

Neratinib Details
Non-small cell lung carcinoma, Lung cancer

Phase 2

Update

Neratinib Details
Bile duct cancer patients with HER2 mutations

Phase 2

Update

Neratinib (HKI-272) + fulvestrant + trastzuzumab Details
Breast cancer, Metastatic breast cancer to brain, Metastatic breast cancer

Phase 2

Update

Phase 2

Update

Alisertib+pembrolizumab Details
Cancer, Head and neck squamous cell carcinoma

Phase 1/2

Data readout